Core Viewpoint - Citius Oncology, Inc. has successfully launched LYMPHIR, generating $3.9 million in revenue for the first fiscal quarter of 2026, marking a significant transition from a development-stage organization to a commercial oncology company [1]. Business Highlights and Subsequent Developments - The company is focused on accelerating physician adoption and expanding patient access to LYMPHIR, with initial distributor sales completed nationwide [1]. - Citius Oncology is preparing to expand its field presence to support a concentrated prescriber base in the rare cancer setting, utilizing an AI-enabled commercial platform for market penetration [1]. - The company is exploring strategic opportunities to enhance long-term shareholder value while managing capital effectively [1]. Financial Highlights for First Quarter 2026 - The net loss for the quarter was $5.5 million, or $(0.06) per share, an improvement from a net loss of $6.7 million, or $(0.09) per share, in the prior-year period [1]. - Stock-based compensation expense increased to $4.0 million, primarily due to equity grants, compared to $1.8 million in the previous year [1]. - General and administrative expenses decreased to $2.9 million from $3.3 million, while research and development expenses were reduced to $1.0 million from $1.3 million [1]. - The company completed a registered offering in December 2025, generating net proceeds of approximately $15.1 million, and reported cash and cash equivalents of $7.3 million as of December 31, 2025 [1]. Market Opportunity - The initial market for LYMPHIR is estimated to exceed $400 million and is considered underserved by existing therapies [1]. - Citius Oncology holds robust intellectual property protections, including orphan drug designation and pending patents for immuno-oncology use, which support its competitive positioning [1].